Focus on Lipids Care

Back to articles

Torcetrapib falters in clinical trials

KEY POINT

Torcetrapib, a novel medication designed by Pfizer to increase HDL cholesterol levels and reduce LDL cholesterol levels, failed to show a decrease in the progression of coronary atherosclerosis in recently released trials. Additionally, treatment with torcetrapib has been associated with significant increases in systolic blood pressure and subsequent cardiovascular events.

SOURCES

Nissen SE et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304–16.

Tall AR. CETP inhibitors to increase HDL cholesterol levels [editorial]. N Engl J Med. 2007;356:1364–6.